
Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients With Advanced or Metastatic Solid Tumors
Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the first patient dosed in its Phase 1 dose escalation and expansion BYON4228.002 clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of novel SIRPα-directed monoclonal antibody (mAb) BYON4228 alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors.
Advertisement
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603807653/en/
Louis Denis, MD, Chief Medical Officer, Byondis
BYON4228 is a potential best-in-class novel mAb that targets and blocks the CD47-SIRPα axis, responsible for tumors' ability to escape from recognition and destruction by the immune system. By targeting SIRPα and not CD47, BYON4228 offers selective targeting of myeloid cells and avoids disruption of other biologically meaningful CD47-dependent interactions. In preclinical studies, BYON4228 was found to potentiate the tumor killing capacity of tumor-targeting mAbs tested without the toxicity associated with CD47 agents.
'Building on strong preclinical data, we believe that there is broad potential for BYON4228 alone and in combination with tumor-targeting mAbs, checkpoint inhibitors and antibody drug conjugates and other modalities across hematological and solid tumors,' said Louis Denis, MD, Chief Medical Officer, Byondis. 'We look forward to evaluating the results of this trial to support the clinical development of BYON4228 alone and in combination with other agents and to bring a new therapeutic option to patients with high unmet medical need.'
Part 1 of the BYON4228.002 trial will evaluate the safety of BYON4228 alone and in combination to determine the maximum tolerated dose (MTD), or optimal biological dose (OBD) if the MTD is not reached, and recommended combination dose regimen(s) for expansion (RDE(s)). The second part of the trial will evaluate the objective tumor response rate (ORR). The secondary objectives of this trial are safety, pharmacokinetics, immunogenicity and preliminary efficacy. The trial will be conducted at multiple sites across Europe, including the United Kingdom, Belgium and Spain.
About BYON4228
BYON4228 is a novel monoclonal antibody (mAb) from Byondis' next generation immuno-oncology (IO) program that targets and blocks the CD47-SIRPα axis, responsible for tumors' ability to escape from recognition and destruction by the immune system. BYON4228 is currently being studied in two Phase 1 Clinical Trials evaluating BYON4228 alone and in combination with Rituximab in patients with Relapsed/Refractory CD20 positive B-cell Non-Hodgkin's Lymphoma (NHL) (NCT05737628) and BYON4228 alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors (NCT06932952).
About Byondis
Driven to improve patients' lives, Byondis is an independent clinical stage fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates and antibody-based therapeutics.
Byondis' broad development portfolio comprises preclinical and early-stage clinical programs. The product candidates combine Byondis' expertise in linker-drug (LD) technology, antibody-drug conjugation, targeted cytotoxic therapy, immunology, and monoclonal antibody (mAb) development. Byondis' expertise covers all preclinical R&D from early lead finding to production of clinical batches of the selected product candidates, which are all done in-house.
The company's headquarters and state-of-the-art R&D and GMP manufacturing facilities are based in Nijmegen, the Netherlands. For more information visit www.byondis.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603807653/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Washington Post
2 hours ago
- Washington Post
Sabres avoid arbitration with Bowen Byram by signing him to a 2-year, $12.5M contract
BUFFALO, N.Y. — The Buffalo Sabres avoided arbitration with Bowen Byram late Monday night by re-signing the restricted free agent defenseman to a two-year contract worth $12.5 million. Byram will count $6.25 million against the salary cap through the 2026-27 NHL season. He was considered a candidate for a trade or an offer sheet from another team before the Sabres elected salary arbitration with him earlier this month.


New York Times
9 hours ago
- New York Times
Ownership group led by Mario Lemieux ‘very interested' in buying back Penguins
PITTSBURGH — A group headlined by former NHL owner and superstar Mario Lemieux remains 'very interested' in buying the Pittsburgh Penguins, according to a source close to the potential ownership group who has been briefed on discussions. The interest in reacquiring the team comes nearly four years after Lemieux and co-owner Ron Burkle sold the Penguins in 2021 to Fenway Sports Group (FSG) in a deal that valued the franchise at $900 million. Last month, The Athletic's Pierre LeBrun reported that former owners Lemieux and Burkle, as well as former chief executive officer David Morehouse, now an adviser with the Pittsburgh Steelers, were exploring the possibility of a deal to buy back the Penguins. Hearing from sources that the group of Ron Burkle, Mario Lemieux and David Morehouse are investigating the possibility of buying back the Penguins from Fenway Sports. Burkle and Lemieux sold the Penguins to Fenway in 2021. Fenway has been looking to sell a partial share. Will be… — Pierre LeBrun (@PierreVLeBrun) June 11, 2025 Since reports surfaced earlier this year that the team was on the block, FSG has stated that it isn't interested in selling the Penguins. 'We've seen the speculation, and as we've previously shared with media, Fenway Sports Group is currently engaged in a process to explore a potential minority investment in the Pittsburgh Penguins,' an FSG spokesperson said in a statement. 'The focus is on identifying a small, passive partner, and that is the current framework under discussion with potential investors.' Advertisement Still, the source said on Monday, the Lemieux group is continuing to consider its financial options and pondering avenues that could see it take control of the Penguins again at some point. 'Maybe it will happen, maybe it won't,' the source said. 'But they're interested. They're very interested. And they're trying to make it happen.' According to sources close to Lemieux and Burkle, NHL commissioner Gary Bettman has been made aware of the group's interest in rejoining the Penguins in an ownership capacity. News that Lemieux is interested in once again owning the Penguins sent shockwaves through Pittsburgh last month. He's not only the greatest athlete in Pittsburgh history but also perhaps more synonymous with the Penguins than any athlete has ever been with any franchise. Lemieux, who led the Penguins to two championships as a player and three more as an owner, still resides and spends most of his time in Pittsburgh. Since selling most of his stake in the team, the notoriously private 59-year-old Lemieux has mostly stayed out of the public eye. He golfs in Florida when he feels like it and spends time with his friends and grandchildren. While undeniably the best player in hockey, Lemieux retired at age 31 in 1997. After purchasing the team in 1999, news broke on Dec. 7, 2000 that he had the itch to play again, some 1,321 days after he had initially walked away from the game. Lemieux and Burkle agreed to sell the Penguins 1,323 days ago. Perhaps Lemieux misses the game. Franchise valuations have skyrocketed in the time since Lemieux and Burkle stepped away. In their most recent rankings, Sportico valued the Penguins at $1.47 billion while Forbes estimated the team's value at $1.75 billion. The NHL's expansion fee — $650 million when the Seattle Kraken joined the league in 2021 — is now reported to be at least $2 billion. Advertisement Re-investing in the Penguins could be a costly endeavor. The group's hope, however, is that FSG might be willing to consider a 'reasonable' price, the source said, considering the Penguins' on-ice struggles and lack of success at the box office. Pittsburgh has failed to reach the playoffs in three consecutive seasons. The Penguins sold just 91.4 percent of their available tickets during the 2024-25 season, the lowest mark of the Sidney Crosby era. They had not played with that percentage of empty seats since 2004, the year before Crosby arrived in Pittsburgh. According to the source, the Lemieux-Burkle group anticipates that the NHL is going to add two expansion teams at some point in the next few years, which would produce a financial windfall for all of the NHL's teams. (Photo of Mario Lemieux: Charles LeClaire / USA Today)


Hamilton Spectator
10 hours ago
- Hamilton Spectator
Professor questions value as Sportsnet Premium streaming price jumps 30 per cent
Sportsnet failed to clearly communicate with fans ahead of a significant price hike to its premium streaming service, a professor says. The broadcaster, owned by Rogers, is raising the price of its Sportsnet+ Premium streaming service starting Sept. 9, with the annual plan jumping from $249.99 to $324.99. The premium tier is the only streaming option in Canada that offers out-of-market NHL games — more than 1,000 matchups — along with in-market regional and national broadcasts. The monthly price is rising from $34.99 to $42.99, meaning fans who subscribe just for the nine-month NHL season will pay more ($386.91) than they would on the annual plan. Brock University sport management professor Michael Naraine says the price hike is frustrating for fans, especially given the lack of communication from Sportsnet. He says the company offered no explanation or incentives — such as advance notice or loyalty discounts — which are common strategies in other industries. 'They just raised prices,' he said. 'They didn't explain to customers or give them a sense of lead time.' By comparison, U.S. viewers can stream out-of-market NHL games via ESPN+ for US$11.99 a month or US$119.99 a year. International fans can access games through for US$14.99 a month. A Sportsnet spokesperson defended the price increase in a statement Monday. 'This update reflects that great value for sports fans looking for the best sports content in the country, while remaining competitively priced with other options in the market,' the statement read. The prices of other Sportsnet packages are also increasing, but not as drastically. A standard Sportsnet subscription, which includes all Toronto Blue Jays content along with national and in-market NHL games, is increasing from $199.99 to $249.00 annually and $24.99 to $29.99 monthly. The increase, Naraine says, was to be expected given Rogers' new 12-year, $11-billion broadcast rights deal with the NHL that begins in 2026–27. Still, Naraine says it's a no-win situation for Sportsnet, because fans are likely to push back no matter what. 'A rational fan would say, 'OK, look, Rogers just paid even more of a premium to get the hockey rights. I expect probably a price increase,'' he said. 'The challenge is, the price is increasing substantially, and the level of service that consumers and fans have been getting over the last couple of years has been suspect — and I think that's really the crux of the issue.' He pointed to stream quality issues and a lack of polish compared to how Apple, Netflix, and Amazon deliver live sports. The hike could push some consumers toward other options, Naraine says — including piracy, password sharing, or turning to the grey market. That might mean using a VPN to access cheaper international streams not intended for Canadian viewers — a legal grey area that bypasses regional broadcast rights. 'When the consumer feels so squeezed, eventually they'll say, 'Look, all right, you know what, I can't afford it no more — screw it,'' he said. 'And we've already started to see that pressure with people (not) going to games. 'But over time, people get accustomed to, 'That's just the cost of doing business,' and people will accept it if they feel that they can take it on. Some people may not feel it, some people will feel it. And right now, Rogers is banking on the fact that maybe over the next few years, people are just going to accept that this is the cost of doing business.' This report by The Canadian Press was first published July 14, 2025.